BioRestorative Therapies' study, which evaluates the benefits of long-term hypoxic culturing of human bone marrow-dervied mesenchymal stem cells to treat disc and spine diseases, was published in the Journal of Translational Medicine.
Here are three details to know:
1. Expanding cells in hypoxic culture conditions affects cell fitness and gene expression that may contribute to cell potency and therapeutic benefits.
2. Hypoxia may be of importance in selection and conditioning cells to be best suited for the specific microenvironment of the disc in order to obtain optimal therapeutic response.
3. The study showed that hypoxic culturing improves mesenchymal stem cell properties and positively influences whole genome expression profiles when referencing the development of cellular therapies targeting the microenvironment of the intervertebral disc.
The product is currently in an FDA-authorized phase two clinical trial, and it will potentially be used as an outpatient treatment in the future.